Fusion Pharm Inc (OTCMKTS:FSPM) Investor Investigation Concerning Potential Securities Laws Violations Announced

If you purchased shares of Fusion Pharm Inc (OTCMKTS:FSPM), you have certain options and you should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this investigation, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
Fusion Pharm
Affected Securities: 

October 7, 2016 (Shareholders Foundation) - An investigation on behalf of investors of Fusion Pharm Inc (OTCMKTS:FSPM) shares over potential securities laws violations by Fusion Pharm Inc and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Fusion Pharm Inc (OTCMKTS:FSPM) concerning whether a series of statements by Fusion Pharm Inc (OTCMKTS:FSPM regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On September 16, 2016, the Securities and Exchange Commission (“SEC”) announced fraud charges against Fusion Pharm Inc and its CEO, Scott M. Dittman, among others, for allegedly misleading investors by recording and trumpeting revenues for purported sales of PharmPods by round-tripping money from illegal stock sales by hidden affiliates.

Shares of Fusion Pharm Inc (OTCMKTS:FSPM) closed on October 7, 2016, at $0.0002 per share.